Eli Lilly, Weight Loss Pill

Eli Lilly bets big on weight-loss pill with $550 million inventory stockpile
Eli Lilly is betting big on its experimental oral weight-loss drug even before reporting data from its late-stage trial by recording nearly $550 million in "pre-launch inventory" in its financial statements,
From pills to new uses, here's what Eli Lilly’s top scientist sees as the future of weight loss drugs
Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.
Eli Lilly (LLY) Stockpiles Weight Loss Pill Ahead of Regulatory Approval
Eli Lilly’s (LLY) new weight loss pill is still in clinical trials and has not yet been approved by regulators. But that hasn’t stopped the
Think Eli Lilly's Stock Is Expensive? Here's Why Selling It Now Could Be a Huge Mistake
The recent surge has been due to the tremendous growth Lilly has achieved due to its highly popular GLP-1 drugs, including Mounjaro (for diabetes) and Zepbound (for weight loss). Together, those two products generated $5.4 billion in sales for Eli Lilly last quarter, or 40% of the top line.
New weight-loss drugs like Mounjaro are hot right now. Eli Lilly's CEO explains why they're so expensive.
David Ricks said drugs like Mounjaro and Zepbound are priced to reflect the costs involved, patent expiry, and the enormous value they offer.
Eli Lilly obesity drug trial participants losing ‘too much weight,’ STAT reports
In ongoing trials of Eli Lilly’s (LLY) next-generation obesity drug, several trial participants are losing too much weight, STAT’s Elaine Chen
Eli Lilly wants to use its weight loss drug windfall to fight Alzheimer's and hearing loss
The weight-loss drug boom has transformed Eli Lilly (LLY), the maker of Zepbound, into the largest healthcare company in the world. Now, the pharma giant wants to reinvest its success with weight-loss meds into tackling some of the world’s toughest health challenges.
Lilly's next obesity drug serves up dramatic weight loss -- and side effects - report
Several individuals enrolled in a phase 3 trial for Eli Lilly's (NYSE:LLY) next-generation obesity drug, retatrutide, say that while they have seen incredible weight loss, it has also come with its share of notable side effects.
How former Tennessee football star Trey Teague's legacy rests with daughter, Lilly, and USJ basketball
Former Tennessee football offensive lineman Trey Teague is sharing lessons learned in Knoxville with his daughter, Lilly, a ...
Digging Into What Hershey and Eli Lilly Told Investors
Eli Lilly 's blockbuster weight loss drugs, and questions about its valuation. Then, Ricky continues his conversation with ...
Designer Reynal salutes Lilly Pulitzer at the new Kips Bay show house in West Palm Beach
Decorator Amanda Reynal's "Lilly Pad" room pays homage to the late fashion icon Lilly Pulitzer at the 2025 Kips Bay Decorator ...
Ibj.com7d
Lebanon planning board to review designs for Lilly’s $4.5B foundry at LEAP District
The 200-acre Lilly Medicine Foundry is expected to add 400 full-time jobs for highly skilled workers, including engineers, ...
Lilly Reinhardt - Classroom Champion Franklin High School
After graduation, Lilly plans on attending either Texas A&M or Baylor and majoring in either Occupational Therapy.
David Lopez Lilly, Joshua Michael Stehle, and Crystal Aguilar slated to appear in court on Friday
David Lopez Lilly, Joshua Michael Stehle, and Crystal Aguilar slated to appear in court on Friday Trump’s endorsement helped ...
Eli Lilly aims to invest in ‘big problems hiding in plain sight' using obesity windfall
Eli Lilly wants to take big swings in Alzheimer’s, ALS, chronic pain and other difficult diseases after its success in ...
WTOP News1d
Columbia visits Brown following Lilly’s 23-point performance
Columbia Lions (12-10, 1-8 Ivy League) at Brown Bears (12-10, 4-5 Ivy League) Providence, Rhode Island; Friday, 7 p.m. EST BETMGM SPORTSBOOK LINE: Bears -5.5; over/under is 152 BOTTOM LINE: Brown ...